Fox Run Management L.L.C. Invests $783,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fox Run Management L.L.C. acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,839 shares of the biopharmaceutical company’s stock, valued at approximately $783,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $53,000. KBC Group NV increased its holdings in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 1,283 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $146,000.

Agios Pharmaceuticals Stock Performance

AGIO opened at $31.30 on Monday. The firm has a market cap of $1.79 billion, a P/E ratio of 2.76 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 52-week low of $27.14 and a 52-week high of $62.58. The business’s fifty day moving average is $33.38 and its 200-day moving average is $41.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.